亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Tenecteplase Thrombolysis for Stroke up to 24 Hours After Onset With Perfusion Imaging Selection: The CHABLIS-T II Randomized Clinical Trial

医学 溶栓 特奈特普酶 改良兰金量表 冲程(发动机) 灌注扫描 随机对照试验 闭塞 心脏病学 内科学 麻醉 灌注 缺血 心肌梗塞 缺血性中风 机械工程 工程类
作者
Xin Cheng,Lan Hong,Longting Lin,Leonid Churilov,Yifeng Ling,Nan Yang,Jianliang Fu,Guozhi Lu,Yunhua Yue,Jin Zhang,Feng Wang,Ziran Wang,Yanxin Zhao,Xiaoyu Zhou,Zhaolong Peng,Danhong Wu,Liandong Zhao,Qijin Zhai,Xiaofei Yu,Qi Fang
出处
期刊:Stroke [Lippincott Williams & Wilkins]
被引量:3
标识
DOI:10.1161/strokeaha.124.048375
摘要

BACKGROUND: Whether it is effective and safe to extend the time window of intravenous thrombolysis up to 24 hours after the last known well is unknown. We aimed to determine the efficacy and safety of tenecteplase in Chinese patients with acute ischemic stroke due to large/medium vessel occlusion within an extended time window. METHODS: Patients with ischemic stroke presenting 4.5 to 24 hours from the last known well, with a favorable penumbral profile and an associated large/medium vessel occlusion, were randomized 1:1 to either 0.25 mg/kg tenecteplase or the best medical treatment. A favorable penumbral profile was defined as a hypoperfusion lesion volume to infarct core volume ratio >1.2, with an absolute volume difference >10 mL, and an ischemic core volume <70 mL. The primary outcome was the achievement of major reperfusion without symptomatic intracranial hemorrhage within 24 to 48 hours post-randomization. Major reperfusion was defined as the restoration of blood flow of >50% of the involved ischemic territory. Secondary outcomes included recanalization, infarct growth, major neurological improvements, change in the National Institutes of Health Stroke Scale score, hemorrhagic transformation within 24 to 48 hours, systemic bleeding at discharge, and modified Rankin Scale (score 0–1, score 0–2, score 5–6, and modified Rankin Scale distribution) at 90 days. The comparison of the primary outcome between groups was conducted using modified Poisson regression with a log-link function and robust error variance, adjusted for time from the last known well to randomization, the site of vessel occlusion, and planned endovascular treatment. RESULTS: Among 224 enrolled patients, 111 were assigned to receive tenecteplase and 113 to receive the best medical treatment (including 23% [n=26] of participants who received intravenous tissue-type plasminogen activator). The mean (SD) age of the tenecteplase group and the best medical treatment group was 64.2 (10.4) and 63.6 (11.0) years old, with 72.1% (n=80) and 70.8% (n=80) male enrolled, respectively. A proportion of 54.9% (n=123) of patients were transferred to the catheter room for preplanned endovascular treatment. The primary outcome occurred in 33.3% (n=37) of the tenecteplase group versus 10.8% (n=12) in the best medical treatment group (adjusted relative risk, 3.0 [95% CI, 1.6–5.7]; P =0.001). Tenecteplase significantly increased the recanalization rate compared with the best medical treatment (35.8% [n=39] versus 14.3% [n=16], adjusted relative risk, 2.5 [95% CI, 1.4–4.4]; P =0.002). There were no significant differences in clinical efficacy outcomes or rates of hemorrhagic transformation between the groups. CONCLUSIONS: Administered at a dose of 0.25 mg/kg intravenously, tenecteplase increased reperfusion without symptomatic intracranial hemorrhage in patients with ischemic stroke selected by imaging in late-time window treatment but did not change clinical outcomes at 90 days. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04516993.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
11秒前
36秒前
51秒前
52秒前
田様应助科研通管家采纳,获得10
1分钟前
量子星尘发布了新的文献求助10
1分钟前
1分钟前
隐形曼青应助noob_采纳,获得10
1分钟前
哈哈哈发布了新的文献求助10
1分钟前
1分钟前
noob_发布了新的文献求助10
1分钟前
科研通AI5应助哈哈哈采纳,获得10
1分钟前
青山完成签到,获得积分10
1分钟前
2分钟前
2分钟前
sunshinelwt发布了新的文献求助10
2分钟前
量子星尘发布了新的文献求助10
2分钟前
2分钟前
去晒月亮完成签到,获得积分20
2分钟前
2分钟前
伯赏元彤发布了新的文献求助10
2分钟前
去晒月亮发布了新的文献求助10
2分钟前
2分钟前
Jimmy发布了新的文献求助10
2分钟前
3分钟前
共享精神应助伯赏元彤采纳,获得10
3分钟前
领导范儿应助科研通管家采纳,获得10
3分钟前
3分钟前
Jimmy完成签到,获得积分10
3分钟前
Billy举报千里求助涉嫌违规
3分钟前
量子星尘发布了新的文献求助10
4分钟前
sunshinelwt完成签到,获得积分10
4分钟前
binyao2024完成签到,获得积分10
4分钟前
4分钟前
胡可完成签到 ,获得积分10
4分钟前
量子星尘发布了新的文献求助30
5分钟前
5分钟前
5分钟前
健康的大船完成签到 ,获得积分10
5分钟前
哈基米发布了新的文献求助10
5分钟前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3976665
求助须知:如何正确求助?哪些是违规求助? 3520770
关于积分的说明 11204786
捐赠科研通 3257528
什么是DOI,文献DOI怎么找? 1798733
邀请新用户注册赠送积分活动 877897
科研通“疑难数据库(出版商)”最低求助积分说明 806629